Treatment after JAKi in patients with rheumatoid arthritis
This study, presented by Professor of Medicine and Rheumatology Janet Pope, highlights the effectiveness of cycling JAK inhibitors (JAKi) of different classes compared with switching to a biological disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA) after failure to the first JAKi.